ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Thunderbolt licenses Astellas B-cell program

by Ann M. Thayer
May 30, 2016 | APPEARED IN VOLUME 94, ISSUE 22

Thunderbolt Pharma has become the first company created by Vitesse Biologics, a drug development collaboration formed by Baxalta, Mayo Clinic, and Velocity Pharmaceutical Development. Thunderbolt has acquired a BAFF/APRIL dual antagonist program from Astellas Pharma. With the three Vitesse partners contributing financially, Thunderbolt will develop the dual antagonists for B-cell-mediated disorders including systemic lupus erythematosus. Baxalta, Mayo Clinic, Velocity, and Astellas are all shareholders in Thunderbolt.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment